ArticleAnnals of surgical oncology2018
Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.
Article in Annals of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Value of Bleeding in Gastrointestinal Stromal Tumors: A Meta-Analysis.Technology in cancer research & treatmentPooled it
- Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.British journal of cancer · 2024Trial
- Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification.Journal of gastric cancer · 2026Review
- Article
- Article
- Survival outcome and impact of delayed imatinib therapy in gastric gastrointestinal stromal tumors.Frontiers in surgery · 2025Article
- Understanding Gastric GIST: From Pathophysiology to Personalized Treatment.Journal of clinical medicine · 2024Review
- Adjuvant therapy for rare rectal gastrointestinal stromal tumors: A case report.Clinical case reports · 2024Article
- The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study.World journal of radiology · 2023Article
- CT features of calcified micro-gastric gastrointestinal stromal tumors: a case series.BMC medical imaging · 2023Article
- Re-appraisal of the universal definition of tumor rupture among patients with high-risk gastrointestinal stromal tumors.Annals of gastroenterological surgery · 2023Article
- Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours.World journal of gastrointestinal surgery · 2023Review
- Oncological outcomes of large gastrointestinal stromal tumors treated by laparoscopic resection.Surgical endoscopy · 2023Article
- Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.Cancer research and treatment · 2022Article
- Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors.Cancers · 2021Review
- Clinicopathological characteristics and prognosis of gastrointestinal stromal tumors containing air-fluid levels.PloS one · 2021Article
- Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review.Translational oncology · 2020Review
- Increased ski expression levels are associated with a higher risk and poor prognosis in patients with gastrointestinal stromal tumors.Oncology letters · 2020Article
- A case of a diverticulum-like giant jejunal gastrointestinal stromal tumour presenting with intraperitoneal peritonitis due to rupture.International journal of surgery case reports · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
backgroundPatients with ruptured gastrointestinal stromal tumor (GIST) are recommended for imatinib adjuvant therapy; however, their clinicopathological features and prognosis in the era of imatinib are unknown. PATIENTS AND
methodsThe study cohort included 665 patients with histologically proven primary GISTs who underwent R0 or R1 surgery between 2003 and 2007; the validation cohort included 182 patients between 2000 and 2014. The definitions of tumor rupture in the study included perforation at tumor site, tumor fracture, piecemeal resection including open biopsy, and macroscopic injuries to the pseudocapsule.
resultsTumor rupture occurred in 21 (3.2%) of 665 and 5 (2.9%) of 182 patients in the study and validation cohort, respectively. Ruptured GISTs were more symptomatic, were larger in size, and had higher mitotic count than nonruptured GISTs but were not associated with tumor location or laparoscopic surgery. GISTs with intraoperative rupture had clinicopathological features and prognostic outcomes similar to those with preoperative rupture. Recurrence rates were higher and median recurrence-free survival (RFS) and overall survival (OS) were shorter with ruptured than nonruptured GIST. Tumor rupture was one of the independent prognostic factors for RFS, but not OS, according to multivariate analysis.
conclusionsRuptured GISTs were symptomatic larger tumors with high mitotic activity, frequent relapse, and shorter RFS. Tumor rupture was an independent prognostic factor for RFS, but not for OS, in the era of imatinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.